Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care.

Petaccia de Macedo M, Melo FM, Ribeiro HSC, Marques MC, Kagohara LT, Begnami MD, Neto JC, Ribeiro JS, Soares FA, Carraro DM, Cunha IW.

Am J Cancer Res. 2017 Sep 1;7(9):1978-1989. eCollection 2017.

2.

SensiScreen®KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations.

Riva A, B├śrgesen M, Guldmann-Christensen M, Hauge Kyneb M, Voogd K, Andersen C, Epistolio S, Merlo E, Yding Wolff T, Hamilton-Dutoit S, Lorenzen J, Christensen UB, Frattini M.

PLoS One. 2017 Jun 21;12(6):e0178027. doi: 10.1371/journal.pone.0178027. eCollection 2017.

3.

Revealing protein networks and gene-drug connectivity in cancer from direct information.

Jiang XL, Martinez-Ledesma E, Morcos F.

Sci Rep. 2017 Jun 16;7(1):3739. doi: 10.1038/s41598-017-04001-3.

4.

Thermodynamic framework to assess low abundance DNA mutation detection by hybridization.

Willems H, Jacobs A, Hadiwikarta WW, Venken T, Valkenborg D, Van Roy N, Vandesompele J, Hooyberghs J.

PLoS One. 2017 May 25;12(5):e0177384. doi: 10.1371/journal.pone.0177384. eCollection 2017.

5.

Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.

Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, Coussens LM, Gast CE, Geltzeiler CB, Hansen L, Kelley KA, Lopez CD, Rana SR, Ruhl R, Tsikitis VL, Vaccaro GM, Wong MH, Mayo SC.

Cell Mol Gastroenterol Hepatol. 2017 Jan 20;3(2):163-173. doi: 10.1016/j.jcmgh.2017.01.006. eCollection 2017 Mar. Review.

6.

Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.

Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, Draganic B, Smith S, Hewitt C, Philimore H, Lucas A, Shi E, Namdarian K, Chan T, Acosta D, Ping-Chang S, Tannapfel A, Reinacher-Schick A, Uhl W, Teschendorf C, Wolters H, Stern J, Viebahn R, Friess H, Janssen KP, Nitsche U, Slotta-Huspenina J, Pohl M, Vangala D, Baraniskin A, Dockhorn-Dworniczak B, Hegewisch-Becker S, Ronga P, Edelstein DL, Jones FS, Hahn S, Fox SB.

Mol Oncol. 2017 Feb;11(2):208-219. doi: 10.1002/1878-0261.12023. Epub 2017 Jan 20.

7.

Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.

Lee YJ, Lee MY, Ruan A, Chen CK, Liu HP, Wang CJ, Chao WR, Han CP.

Oncotarget. 2016 Dec 13;7(50):82097-82103. doi: 10.18632/oncotarget.13449.

8.

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.

Boleij A, Tack V, Taylor A, Kafatos G, Jenkins-Anderson S, Tembuyser L, Dequeker E, van Krieken JH.

BMC Cancer. 2016 Oct 26;16(1):825.

9.

Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective.

Chen G, Yang Z, Eshleman JR, Netto GJ, Lin MT.

Biomed Res Int. 2016;2016:9850690. Epub 2016 Sep 6. Review.

10.

Mixed adenoneuroendocrine carcinoma of the ampulla of Vater: A case report.

Max N, Rothe A, Langner C.

Mol Clin Oncol. 2016 Jul;5(1):95-98. Epub 2016 Apr 14.

11.

Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors.

Sloane HS, Landers JP, Kelly KA.

J Mol Diagn. 2016 Jul;18(4):546-53. doi: 10.1016/j.jmoldx.2016.02.004. Epub 2016 Jun 8.

12.

BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.

Roma C, Rachiglio AM, Pasquale R, Fenizia F, Iannaccone A, Tatangelo F, Antinolfi G, Parrella P, Graziano P, Sabatino L, Colantuoni V, Botti G, Maiello E, Normanno N.

Cancer Biol Ther. 2016 Aug 2;17(8):840-8. doi: 10.1080/15384047.2016.1195048.

13.

BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.

Nam SK, Yun S, Koh J, Kwak Y, Seo AN, Park KU, Kim DW, Kang SB, Kim WH, Lee HS.

PLoS One. 2016 Mar 18;11(3):e0151865. doi: 10.1371/journal.pone.0151865. eCollection 2016.

14.

Novel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer.

Sharma A, Zhang G, Aslam S, Yu K, Chee M, Palma JF.

Mol Diagn Ther. 2016 Jun;20(3):231-40. doi: 10.1007/s40291-016-0193-4.

15.
16.

RAS testing in metastatic colorectal cancer: advances in Europe.

Van Krieken JH, Rouleau E, Ligtenberg MJ, Normanno N, Patterson SD, Jung A.

Virchows Arch. 2016 Apr;468(4):383-96. doi: 10.1007/s00428-015-1876-7. Epub 2015 Nov 16. Review.

17.

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.

Normanno N, Pinto C, Castiglione F, Fenizia F, Barberis M, Marchetti A, Fontanini G, De Rosa G, Taddei GL.

J Transl Med. 2015 Sep 3;13:287. doi: 10.1186/s12967-015-0655-1.

18.

Precision medicine in colorectal cancer: the molecular profile alters treatment strategies.

Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA.

Ther Adv Med Oncol. 2015 Sep;7(5):252-62. doi: 10.1177/1758834015591952. Review.

19.

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?

Saridaki Z, Saegart X, De Vriendt V, Hatzidaki D, Palmans S, De Smedt L, De Hertogh G, Tejpar S.

Br J Cancer. 2015 Sep 15;113(6):914-20. doi: 10.1038/bjc.2015.307. Epub 2015 Sep 1.

20.

Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.

Zhou LN, Wu N, Liang Y, Gao K, Li XY, Zhang LF.

World J Surg Oncol. 2015 Mar 15;13:111. doi: 10.1186/s12957-015-0505-x.

Supplemental Content

Support Center